Navigation Links
Plasma protein Therapies Association Focuses Attention on Donors and Facilities

Texas Lawmakers Proclaimed August as "Plasma Protein Therapies Month"

Texas (Vocus) August 19, 2009 -- The contributions of voluntary plasma donors and the issue of treating critically ill patients with plasma protein therapies was recognized by Texas lawmakers in June when they proclaimed August "Plasma Protein Therapies Month" in the Lone Star State.

"Patients requiring plasma protein therapies have serious diseases and disorders and need to be assured that they will continue to have access to those treatments," said Josh Penrod, Vice President, Source for the Plasma Protein Therapy Association. "The collection of high-quality plasma from dedicated donors, like those in Texas, is a crucial component in the production of these therapies."

Plasma protein therapies include a treatment for primary immunodeficiency diseases, alpha-1 antitrypsin deficiency, also known as genetic emphysema, and for blood clotting disorders such as hemophilia. In addition, a plasma protein therapy is used in critical care settings, when treating severe trauma, burns and during major surgery. Plasma protein therapies refer to plasma-derived therapies and their recombinant analogs.

Hundreds of Texans each year donate plasma at 48 collection centers in Texas to help create therapies that save the lives of thousands of people across the nation. In fact, Texas has the most plasma donation centers in the nation.

This recognition raises awareness of the rare, genetic diseases treated with the therapies and to honor plasma donors across the state for their contributions to the little known treatments that benefit patients with a variety of genetic diseases and those in critical care settings including trauma and major surgery.

The Plasma Protein Therapies Association, a trade association representing plasma protein therapy manufacturers and the source plasma collection industry.

For more information about plasma protein therapies the diseases they treat and donating plasma, please go to or

The Plasma Protein Therapeutics Association (PPTA) is the trade association and standard setting organization for the world's major producers of plasma derived and recombinant analog therapies (collectively, "plasma protein therapies"). These therapies are used by more than 1 million people worldwide each year to treat a variety of diseases and serious medical conditions. PPTA members produce over 80 percent of the plasma therapies for the United States market and more than 60 percent worldwide. Some of the critical therapies produced by PPTA members include: blood clotting factors for people with hemophilia, immune globulin intravenous used to prevent infections in people with immune deficiencies and other serious conditions, and alpha 1 proteinase inhibitor used to treat people with alpha 1 antitrypsin deficiency, also known as genetic emphysema.

Kym H. Kilbourne
(443) 458 4682
(443) 995-2102 (cellular)

Kara Flynn
(443) 458-4669
(443) 370-1177


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation
2. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
3. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
4. Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program
5. Toxoplasma infection increases risk of schizophrenia, study suggests
6. Data From Antheras Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions
7. Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars
8. China Biologic Products Announces Approval for the Relocation of Fang Cheng Plasma Collection Station and for the Procurement of Excess Clinical Plasma
9. Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
10. Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
11. Grifols Biomat USA Opens New Plasma Donor Center in Lincoln
Post Your Comments:
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... , ... November 25, 2015 , ... For the first ... “ Two Organizations, One Beat ” campaign. The partnership between the two groups began ... aid in MAP International’s cause. , MAP International was founded in 1954 and is ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Smiles by ... TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the ... the great success Botox® delivers to those suffering with discomfort, soreness, and pain as ...
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 USP ... hazardous drug preparations (e.g. pharmacists, pharmacy technicians, nurses, ... veterinary technicians). The chapter also covers all entities ... (e.g., pharmacies, hospitals, other healthcare institutions, patient treatment ... --> --> What ...
(Date:11/25/2015)... 25, 2015 Asia ... which BioLight and the New Investors will make a ... via a private placement. The financing will help IOPtima ... system used in the treatment of glaucoma, as well ... the IOPtimate™ system with the U.S. Food and Drug ...
(Date:11/25/2015)... LONDON , November 25, 2015 Developmental, ... key role in boosting the profitability of pharmaceutical products, ... Developmental, commercial, and regulatory/legal strategies all play ... says GBI Research . --> ... all play a key role in boosting the profitability of pharmaceutical ...
Breaking Medicine Technology: